Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
Providers are up to three times more likely to trust the opinion of humans over AI, even when the algorithm is proven to detect more cancerous lesions than radiologists.
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.
Briefly trained in point-of-care cardiac ultrasound, 72% of second-year medical students obtained clinical-quality views from a mannequin and 61% made the correct diagnosis in a volunteer simulated patient.
Orthopedic cone-beam CT supplier CurveBeam AI has received the FDA’s breakthrough device designation for software that computes risk of fracture in patients with osteopenia.
Nuclear radiologists are overall confident in the scientific soundness of studies published within their field. Those working in Asia are especially trusting. However ...
The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.
“Results of this case-control study suggest that even for maximum univariate biological differences, deviations between patients with MDD and healthy controls were remarkably small," experts shared in JAMA Psychiatry.
